Navigation Links
Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
Date:10/17/2007

onically debilitating condition that affects no more than five in 10,000 persons in the European Union.

About Picoplatin

Picoplatin is a new generation platinum chemotherapy agent. It was designed to overcome platinum resistance and to prolong the time to relapse after chemotherapy in the treatment of solid tumors, and to have an improved safety profile compared with existing platinum-based chemotherapeutics. Poniard received orphan drug designation from the FDA in November 2005 for picoplatin for the treatment of SCLC.

In addition to the SPEAR trial of intravenous picoplatin in SCLC, Poniard is also evaluating intravenous picoplatin in an ongoing Phase 1 clinical trial as a first-line treatment for metastatic colorectal cancer and in an ongoing Phase 2 trial in combination with docetaxel (Taxotere(R)) and prednisone in patients with metastatic hormone-refractory prostate cancer. Oral picoplatin is being evaluated in a Phase 1 clinical trial in solid tumors.

About Small Cell Lung Cancer

SCLC is the most aggressive and deadly form of lung cancer and accounts for approximately 20 percent of all lung cancer cases. The current two-year survival rate for patients with extensive SCLC is less than 10 percent with current management options. The estimated incidence of lung cancer in the United States in 2006 was 174,500, according to the National Cancer Institute. The estimated incidence in Europe in 2006 was 386,300, according to the International Agency for Research on Cancer.

SCLC is currently treated with platinum therapies, but many patients do not respond, and if they do respond, they typically relapse within a short time after treatment. There is currently no FDA-approved therapy and no consistent and effective therapy for SCLC patients who have platinum-resistant or -refractory disease after treatment failure with first-line combination therapy with either cisplatin or carboplatin. No new drugs have been approved by the FDA for th
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Speaker announces business members of IT Task Force
4. Doyle announces technology tax credits for Berbee
5. Doyle announces new energy, global warming policies
6. Doyle announces $80M renewable energy strategy
7. GE announces first installation of Discovery VCT
8. UWM announces winners of RGI awards
9. Third Wave announces two senior management appointments
10. Mirus announces new method for making antibodies
11. Merge announces sofware updates, upcoming acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... , Sept. 1, 2015 ... cancer death in American men. One in ... and 233,000 new cases are diagnosed annually. That ... are using a powerful new technique, MRI Fusion ... and large cancer lesions, treating only the affected ...
(Date:9/1/2015)... The Dohmen Company today announced the ... as Chief Science Officer (CSO) of Dohmen Life ... Dr. Floyd will lead Dohmen,s growing regulatory consulting ... and post approval outsourced services in quality, regulatory, ... Floyd brings decades of experience leading global regulatory ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... has been discovered by researchers at the Keck Graduate Institute and its collaborators. ... diseases. , The findings were published online on August 27 by Scientific Reports, ...
(Date:8/31/2015)... , Aug. 31, 2015 /PRNewswire/ - BIOREM Inc. (TSXV: ... totalling $5.7 million. The orders are for air emission abatement projects ... particular note is a large order for a municipality in ... will be replacing a competitor,s system that failed to meet ... our engineered solutions," said Derek S. Webb , President ...
Breaking Biology Technology:September Is Prostate Cancer Awareness Month 2September Is Prostate Cancer Awareness Month 3September Is Prostate Cancer Awareness Month 4Dohmen Life Science Services Appoints Eric Floyd, Ph.D. as Chief Science Officer 2Dohmen Life Science Services Appoints Eric Floyd, Ph.D. as Chief Science Officer 3Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 2Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 3Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 4
... 2011 VIVUS, Inc. (Nasdaq: VVUS ), ... therapeutic products, today reported its financial results for the first quarter ... the quarter ended March 31, 2011, VIVUS reported a net loss ... net loss of $18.8 million or $0.23 per share for the ...
... 2, 2011 Richard Resnick, GenomeQuest,s chief executive ... May 3, 2011, at the Biomarker World Congress ... Sequencing on Companion Diagnostics" for pharmaceutical and biotechnology ... and data management technologies. The Biomarker ...
... 2, 2011 Dyadic International, Inc. ("Dyadic") (OTC ... the discovery, development, manufacture and sale of enzyme ... industrial enzyme industries, announced today that its research ... has entered into a research agreement with Sanofi ...
Cached Biology Technology:VIVUS Reports First Quarter 2011 Financial Results 2VIVUS Reports First Quarter 2011 Financial Results 3VIVUS Reports First Quarter 2011 Financial Results 4VIVUS Reports First Quarter 2011 Financial Results 5GenomeQuest to Lead Biomarker World Congress Panel on Applying Whole Genome Sequencing to Developing Companion Diagnostics 2Dyadic Netherlands Enters Into R&D Collaboration With Sanofi Pasteur and EnGen Bio 2
(Date:9/1/2015)... Calif. , Sept. 1, 2015  Automation ... travelers during airport passenger screening. This is the ... passenger screening process will become unintrusive. An assortment ... based on voluntary background investigations will transform the ... Frost & Sullivan, Global Airport Passenger Screening ...
(Date:8/31/2015)... BURNABY, Canada , August 31, 2015 ... use of biometrics technology in government digitization projects to drive ... According to a recently published TechSci Research report, " India ... India is projected to grow at ... in the market is anticipated on account of extensive use ...
(Date:8/31/2015)... , Aug. 31, 2015 Research and Markets ... "Saudi Arabia Biomedical Sensors Market - Growth, Trends ... The Saudi Arabia Biomedical Sensors market is ... of 3.64% over the period 2014-2020 The ... to the genetic formulation of each individual. These sensors ...
Breaking Biology News(10 mins):The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 2The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 3The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 4India Biometrics Market to Grow at Over 35% Through 2020, Says TechSci Research 2India Biometrics Market to Grow at Over 35% Through 2020, Says TechSci Research 3Saudi Arabia Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts (2014-2020) 2
... look cute. They have a thick fur, fly somewhat ... They are very much appreciated by farmers as keen ... honeybee populations, the buff-tailed bumblebee, Bombus terrestris , ... pollination of fruit and vegetable crops both inside and ...
... Israel decades ago, but worldwide the disease continues to ... people worldwide and killed an estimated 660,000, mostly African ... extent focused on advanced science and vaccine development. But ... Jerusalem believe a parallel approach -- based on methods ...
... REDDING, Calif.As trees grow larger in even-aged stands, competition ... for soil moisture, nutrients, and sunlight. Competition also increases ... leads to a buildup of dead fuels. A recent ... the U.S. Forest Service,s Pacific Southwest Research Station, considered ...
Cached Biology News:Peaceful bumblebee becomes invasive 2Peaceful bumblebee becomes invasive 3Malaria conference looks to Israel's past for modern solutions 2Lowering stand density reduces mortality of ponderosa pine stands 2
Anti Autotaxin /ENPP2 , - (Rabbit)...
... 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose Pale yellow solid. An N-nitroso-containing ... nitric oxide donor in pancreatic islets. ... Causes DNA alkylation and DNA strand ... ≥95% by HPLC. Soluble in H ...
Mouse monoclonal antibody to CDC2L5 - cell division cycle 2-like 5 (cholinesterase-related cell division controller)...
... The pACHLT-A-BFP Baculovirus Transfer Vector is a derivative ... the gene for blue fluorescent protein (BFP), followed ... site (MCS).,Foreign genes are expressed as BFP-6xHis fusion ... restriction enzyme,sites (EcoR I, Stu I, Sac I, ...
Biology Products: